Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022
April 2022
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
Luhan Yang & George Church: Ten billion dollars should be spent on anti-aging research
June 2021
Qihan Biotech Raises Additional USD 67 Million in Series A++ Financing. Funds to Advance Pipeline of Novel Cell and Organ Therapies
March 2021
Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.
Best wishes for the Spring Festival from the Scientific Advisory Board of Qihan
February 2021
Happy new year!
Luhan Yang-Lecture of Harvard CSSA
November 2020
Harvard Chinese Students and Scholars Association
Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies
October 2020
Qihan Biotech today disclosed the initiation of a program to create immunologically privileged human stem cells to enable the development of improved allogeneic cell therapies.
Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees
September 2020
Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees.
Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering
September 2020
In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).
Co-founder Dr. George Church visited Qihan to lead SAB meetings
October 2019
On October 23, 2019, Dr. George Church visited Qihan, and he learned about the team’s research progress and gave a scientific speech on cutting-edge gene-editing technology.